TrialThe oncologist2019

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.

Eric Van Cutsem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.